Using Large-Scale Data, AI to Assess Effective Migraine Treatment Options: Chia-Chun Chiang, MD

Video

The associate professor of neurology at Mayo Clinic Rochester provided perspective on a new study presented at the 2023 AAN Annual Meeting assessing the treatment effectiveness of real-world patients with migraine. [WATCH TIME: 4 minutes]

WATCH TIME: 4 minutes

"In this study, we employed a generalized linear mixed model, specifically a two-level nested logistic regression model, which can be considered a type of machine learning approach as well. But in the future, there are certainly a lot of different types of machine learning applications and AI applications that can be used in this type of data."

Over the years, the toolbox of therapeutic options for patients with migraine has grown exponentially, headlined by recent calcitonin gene-related peptide (CGRP) antagonists. Using a big-data approach, a recently conducted study simultaneously compared patient-reported treatment effectiveness of 25 acute migraine medications. Across 7 classes of acetaminophen, nonsteroidal anti-inflammatory drugs, triptans, combination analgesics, ergots, anti-emetics, and opioids, 10,842,795 migraine attacks were extracted for data.

Presented at the 2023 American Academy of Neurology (AAN) Annual Meeting, held April 22-27, in Boston, Massachusetts, the study showed that triptans (OR, 4.8), ergots (OR, 3.02), and anti-emetics (OR, 2.67) were the top 3 classes of medications with the highest effectiveness. Led by Chia-Chun Chiang, MD, the OR of treatment effectiveness was assessed through a 2-level nested logistic regression model that was adjusted on concurrent medications and the covariance within the same user.

Chiang, an associate professor of neurology at Mayo Clinic Rochester, sat down at the meeting to discuss the reasons for why her and her colleagues conducted this study, and the significance of the findings. She noted that gepants and ditans were not included because of the relatively lower numbers of usage when data was extracted. Additionally, Chiang spoke on the most notable data points migraine specialists should be aware of, and ways big-data approaches can effectively impact the field as technology continues to advance.

Click here for more coverage of AAN 2023.

REFERENCE
1. Chiang C, Fang X, Horvath Z. et al. Simultaneous comparisons of 25 acute migraine medications: a big data analysis of 10 million patient self-reported treatment records from a migraine smartphone application. Presented at: 2023 AAN Annual Meeting; April 22-27; Boston, MA. 002258
Related Videos
Michael Levy, MD, PhD
Michael Kaplitt, MD, PhD
Michael Kaplitt, MD, PhD
video 4 - "Amyloid Cascade Hypothesis of Alzheimer’s Disease"
Video 3 - "Amyloid Precursor Protein and Amyloid Beta Species in Alzheimer’s Disease"
Svetlana Blitshteyn, MD, FAAN, director and founder of Dysautonomia Clinic
© 2024 MJH Life Sciences

All rights reserved.